- Ceapro (TSXV:CZO) announced positive results from a research collaboration with the Angiogenesis Foundation conducted with colleagues at the University of Arizona
- The researchers concluded that oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation
- The Foundation is an independent 501(c)(3) scientific organization that drives innovations in health promotion, disease prevention, and disease treatment through research, education, and advocacy
- Ceapro is a Canadian biotechnology company
- Ceapro Inc. (TSXV:CZO) is up 5.36 per cent, trading at C$0.59 per share at 3:37 pm ET
Edmonton, Alberta, based Ceapro (TSXV:CZO) announced positive results from a research collaboration with the Angiogenesis Foundation conducted with colleagues at the University of Arizona.
The aim of this study was to assess the in vivo bioactivity of Ceapro products on angiogenesis, wound healing, tissue repair, and regeneration.
The study was based on key learnings from an earlier in vitro study where researchers from the Foundation demonstrated that Ceapro’s AVE and BG stimulate proliferation of vascular endothelial cells (angiogenesis) which is a critical step in wound healing.
Research Findings
Results from the current in vivo study showed that both 1 per cent AVE and 1 per cent BG treatment resulted in earlier wound closure in mice compared to controls. Tissue analysis revealed that:
- 1 per cent AVE treatment resulted in decreased tissue inflammation and the healed tissue had less scarring and an architecture more resembling normal tissue compared to that of scar tissue after control treatment.
- 1 per cent BG-treated tissue exhibited more microvessels (angiogenesis) and the presence of endothelial progenitor cells, compared to control mice. BG treatment also resulted in increased collagen fiber width and length, more resembling normal tissue architecture compared to scar tissue after control treatment.
The researchers concluded that oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation.
About the Angiogenesis Foundation
Founded in 1994, the Angiogenesis Foundation is a group of physicians. It includes Dr. William Li who is currently the CEO of the Foundation and a board member of Ceapro Inc.
The Foundation is an independent 501(c)(3) scientific organization that drives innovations in health promotion, disease prevention, and disease treatment through research, education, and advocacy.
The Foundation has experience in developing rigorous, high-impact scientific studies, including in the vascular and immuno-inflammatory arenas that underlie chronic diseases in oncology, cardiovascular diseases, and wound healing. It has presented its results at national and international meetings, and published in top tier scientific and clinical journals, including Science, Nature, Lancet, and New England Journal of Medicine.
About Ceapro
Ceapro is a Canadian biotechnology company. It develops and commercializes active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries.
The company has a broad range of expertise in natural product chemistry microbiology biochemistry immunology and process engineering. Its two value-driving products oat beta glucan and avenanthramides are found in many household names cosmetic and personal care brands.
Ceapro Inc. (TSXV:CZO) Stock is up 5.36 per cent, trading at C$0.59 per share at 3:37 pm ET.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.